Table 3.

Risks of first occurrence of primary and secondary outcome events during follow-up

	Start antiplatelet therapy (n=268)	Avoid antiplatelet therapy (n=268)	Log-rank test p value	Unadjusted analysis		Adjusted analysis
				HR (95% CI)	p value	HR (95% CI)	p value
Primary outcome
Recurrent symptomatic spontaneous intracerebral haemorrhage	12	23	0·057	0·51 (0·26–1·03)	0·062	0·51 (0·25–1·03)	0·060
Sensitivity analyses of the primary outcome
Recurrent symptomatic spontaneous intracerebral haemorrhage or symptomatic stroke of uncertain subtype	12	24	0·041	0·49 (0·25–0·99)	0·046	0·49 (0·24–0·98)	0·044
Recurrent symptomatic spontaneous intracerebral haemorrhage or death of undetermined cause	13	25	0·047	0·51 (0·26–1·00)	0·051	0·51 (0·26–0·99)	0·048
Secondary outcomes
All major haemorrhagic events (all types of symptomatic spontaneous or traumatic intracranial haemorrhage, or symptomatic major extracranial haemorrhage)	18	25	0·27	0·71 (0·39–1·30)	0·27	0·71 (0·39–1·30)	0·27
All major occlusive vascular events (ischaemic stroke; myocardial infarction; mesenteric ischaemia; peripheral arterial occlusion; deep vein thrombosis; pulmonary embolism; or carotid, coronary, or peripheral arterial revascularisation procedures)	39	38	0·97	1·01 (0·65–1·58)	0·97	1·02 (0·65–1·60)	0·92
All major haemorrhagic or occlusive vascular events	54	61	0·42	0·86 (0·60–1·24)	0·42	0·86 (0·60–1·24)	0·43
Major occlusive vascular events*	45	52	0·39	0·84 (0·56–1·25)	0·39	0·84 (0·56–1·25)	0·39
Major vascular events (as defined by the Antithrombotic Trialists' Collaboration)	45	65	0·026	0·65 (0·45–0·95)	0·027	0·65 (0·44–0·95)	0·025

HR=hazard ratio.

^*As defined in the trial protocol.